ATNM News and Press, Actinium Pharmaceuticals Inc. From 04/22/21

We all make investment mistakes, but some hurt more than others. Some mistakes can be subtle and insidious if not addressed early on. The key is to learn from all of them to grow into a better investor. Today, I present three investment mistakes that cost me a fortune. I h...

Actinium to Participate in the Cell & Gene Meeting on the Mediterranean Actinium to Participate in the Cell & Gene Meeting on the Mediterranean - Actinium to highlight Iomab-ACT program for targeted conditioning for CAR-T, adoptive cell therapies, and gene therapies ...

Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML - Proof-of-concept Phase 1 data expected in 2H:2021 will evaluate safety, response rates, MRD negativity and cytogenetic profiles - Complete ...

Actinium Pharmaceuticals' (ATNM) collaborator, Memorial Sloan Kettering Cancer Center ((MSK)) has commenced patient enrollment in Phase 1 study evaluating Iomab-ACT for targeted conditioning prior to treatment with MSK's CD19 targeted CAR T-cell 19-28z.Iomab-ACT is a low dose version of Actin...

Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy - CAR T-cell therapy manufacturing commenced with Iomab-ACT conditioning and patient treatment scheduled for early Q2:2021 - Clinical proof-of-co...

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC - Positive preclinical data support continued development with strong potential in bone marrow transplant, adoptive cell therapy and gene therapy...

Today, we take our first in-depth look at Actinium Pharmaceuticals, a small-cap developmental concern based in New York City. The company has numerous "shots on goal" and the stock is far below analyst price targets. A full analysis follows in the paragraphs below. For furth...

Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer - Mr. Kubik joins Actinium with over 25 years of experience in transformative and award-winning BD and M&A transactions - Proven deal making abilities in the empowered antibody, biologics and gen...

Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference PR Newswire NEW YORK , March 2, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the ...

Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting ...